Figure 6.

Effects of MTH treatment on BCL11A-XL and globin gene expression in murine FLCs and ErPCs from β–thalassemia patients. (A) FLCs were treated for 4 days with 2% DMSO or 400 nmol/L MTH. The proportion of benzidine-positive cells (left), content of globin mRNAs (middle), and content of Bcl11a (right) were evaluated. (B) ErPCs from three β⁺- and four β⁰-thalassemia patients were isolated and cultured for 5 days with 30 nmol/L MTH. BCL11A-XL and γ-globin mRNAs were analyzed by RT-qPCR. (C) Relationship between MTH concentration and content of BCL11A-XL and γ-globin mRNAs in ErPCs from a β⁰39/β⁰39 thalassemia patient. ErPCs were cultured for 5 days with increasing concentrations of MTH, RNA was isolated, and RT-qPCR performed. The data (A) represent averages ± SD of three independent cultures.